Petros Pharmaceuticals

Equities

PTPI

US71678J2096

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.6399 ^USD	0.00%		-4.51%	-54.62%

Apr. 23	Petros, Lemonaid Health Collaborate to Expand Stendra Availability	MT
Apr. 23	Petros Pharmaceuticals, Inc. Expands Online Distribution for Prescription STENDRA Through New Agreement with Lemonaid Health	CI

Thinking about buying stock in Helius Medical Technologies, Peraso, GDS Holdings, Everbridge, or Petros Pharmaceuticals?

February 06, 2024 at 09:32 am EST

NEW YORK, Feb. 6, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HSDT, PRSO, GDS, EVBG, and PTPI.

InvestorsObserver (PRNewsfoto/InvestorsObserver)

To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link.

HSDT: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=HSDT&prnumber=202402060
PRSO: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=PRSO&prnumber=202402060
GDS: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=GDS&prnumber=202402060
EVBG: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=EVBG&prnumber=202402060
PTPI: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=PTPI&prnumber=202402060

(Note: You may have to copy this link into your browser then press the [ENTER] key.)

InvestorsObserver's PriceWatch Alerts are based on our proprietary scoring methodology. Each stock is evaluated based on short-term technical, long-term technical and fundamental factors. Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment.

InvestorsObserver provides patented technology to some of the biggest names on Wall Street and creates world-class investing tools for the self-directed investor on Main Street. We have a wide range of tools to help investors make smarter decisions when investing in stocks or options.

View original content to download multimedia:https://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-helius-medical-technologies-peraso-gds-holdings-everbridge-or-petros-pharmaceuticals-302054614.html

SOURCE InvestorsObserver

Latest news about Petros Pharmaceuticals

Petros, Lemonaid Health Collaborate to Expand Stendra Availability	Apr. 23	MT
Petros Pharmaceuticals, Inc. Expands Online Distribution for Prescription STENDRA Through New Agreement with Lemonaid Health	Apr. 23	CI
Petros Gets 'Positive' FDA Response Over Technology Component in Stendra OTC Process	Apr. 16	MT
Petros Pharmaceuticals Receives Positive Response from Fda Following Recent Demonstration of Technology Component in Pursuit of Otc Status for Stendra(R)	Apr. 16	CI
Petros Pharmaceuticals, Inc. Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA as it Pursues OTC Status	Apr. 02	CI
Petros Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Petros Pharmaceuticals Enters into Ai Licensing Agreement with Leading Multi-Billion-Dollar Software Provider	Feb. 14	CI
Top Premarket Gainers	Jan. 30	MT
Petros Pharmaceuticals, Inc. Announces Successful Completion of the Initial Cohort of A Phase 2 Equivalent Self-Selection Study	Jan. 17	CI
Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) the First Erectile Dysfunction Medication to Achieve OTC Status	Dec. 12	CI
Maxim Initiates Petros Pharma at Buy Rating With $4 Price Target	Dec. 08	MT
Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug Crestor's (Rosuvastatin) OTC Switch Technology Provider	Dec. 05	CI
Petros Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 15	CI
Petros Pharmaceuticals Announces to Develop Artificial Intelligence Technology for Phase 2 Equivalent Study for STENDRA(R)	23-10-30	CI
Petros Pharmaceuticals, Inc. Initiates Self-Selection (Phase 2-Equivalent) Study for STENDRA	23-10-19	CI
Petros Pharmaceuticals Announces Positive Outcomes in Label Comprehension Study for Potential Otc Stendra Label	23-10-04	CI
Top Premarket Decliners	23-10-04	MT
Petros Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Petros Pharmaceuticals Secures $15 Million Private Placement Financing	23-07-14	MT
Petros Pharmaceuticals, Inc. announced that it has received $15 million in funding	23-07-12	CI
Petros Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Top Premarket Decliners	23-04-17	MT
Wall Street Set to Open Lower, March Retail Sales Fall More Than Expected	23-04-14	MT
US Equity Futures Mixed Ahead of Retail Sales, Industrial Production, Consumer Sentiment Reports	23-04-14	MT
Top Premarket Gainers	23-04-14	MT

Chart Petros Pharmaceuticals

Duration

Period

More charts

Company Profile

Petros Pharmaceuticals, Inc. is a pharmaceutical company focused on men's health therapeutics with a range of commercial capabilities including sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing, and distribution. The Company is also focused on identifying, developing, acquiring, and commercializing therapeutics for men's health issues, including, erectile dysfunction (ED), endothelial dysfunction, psychosexual and psychosocial ailments, peyronie's disease, hormone health, and substance use disorders. The Company also markets its own line of ED products in the form of vacuum erection device (VED) products through its subsidiaries, Timm Medical, Inc. In addition, its ED products, the Company is focused on identifying and developing other pharmaceuticals to advance men's health, which is H100, which is the topical formulation candidate for the treatment of acute peyronie's disease.

Sector

More about the company